Investigation – Page 16

CAPA ineffectiveness during FDA inspection: regulatory remediation strategy

Addressing the Challenges of CAPA Ineffectiveness During FDA Inspections in Pharmaceutical Manufacturing In the highly regulated realm of pharmaceutical manufacturing, Corrective and Preventive Actions (CAPA) are crucial to maintaining compliance…

Design control deficiency during ISO 13485 audit: CAPA system strengthening

Addressing Design Control Deficiencies Identified During ISO 13485 Audits Design control deficiencies are a recurring issue that can significantly impact a company’s ability to bring medical devices to market effectively.…

Process validation failure during post-market surveillance: regulatory remediation strategy

Addressing Process Validation Failures in Post-Market Surveillance: A Comprehensive Investigation Guide In the complex world of pharmaceutical manufacturing and quality assurance, the repercussions of process validation failures during post-market surveillance…

CAPA ineffectiveness during ISO 13485 audit: inspection-ready documentation

Addressing CAPA Ineffectiveness During ISO 13485 Audits: A Step-by-Step Investigation CAPA (Corrective and Preventive Action) systems are vital for maintaining the compliance and effectiveness of quality management systems in medical…

CAPA ineffectiveness during FDA inspection: inspection-ready documentation

Understanding CAPA Ineffectiveness During FDA Inspections In the complex landscape of pharmaceutical manufacturing, the effectiveness of a Corrective and Preventive Action (CAPA) system is critical to maintaining regulatory compliance. When…

Inventory reconciliation mismatch during controlled drug manufacturing: inspection-ready documentation

Resolving Inventory Discrepancies in Controlled Drug Manufacturing: An Inspection-Ready Approach Inventory reconciliation mismatches can pose significant challenges in controlled drug manufacturing, raising alarms during FDA, EMA, or MHRA inspections. Such…

Process validation failure during FDA inspection: CAPA system strengthening

Addressing Process Validation Failures Identified During FDA Inspections: Strengthening Your CAPA System Process validation failures during FDA inspections can serve as significant signals of underlying issues within your manufacturing processes.…

Occupational exposure limit breach during inspection prep: risk assessment for patient safety

Risk Assessment and Investigation of Occupational Exposure Limit Breaches During Inspection Preparation Occupational exposure limit (OEL) breaches present a significant concern in pharmaceutical manufacturing, particularly in high-stakes environments such as…

CAPA ineffectiveness during post-market surveillance: inspection-ready documentation

Addressing CAPA Ineffectiveness in Post-Market Surveillance: A Comprehensive Investigation Post-market surveillance (PMS) plays a critical role in ensuring the ongoing safety and efficacy of medical devices. However, instances of CAPA…

Chain of custody breach during controlled drug manufacturing: regulatory enforcement risk mitigation

Mitigation Strategies for Chain of Custody Breaches in Controlled Drug Manufacturing Chain of custody breaches during controlled drug manufacturing can pose significant regulatory enforcement risks, leading to potential regulatory scrutiny…

Supplier qualification gap during FDA inspection: CAPA system strengthening

Addressing Supplier Qualification Gaps Identified during FDA Inspections and Strengthening CAPA Systems During the complexities of pharmaceutical manufacturing, gaps in supplier qualification can often lead to compliance issues during regulatory…

Labeling non-compliance during warehousing: inspection-ready documentation

Addressing Labeling Non-Compliance in Pharmaceutical Warehousing: A Step-by-Step Investigation Framework Labeling non-compliance during warehousing can lead to significant regulatory challenges and operational disruptions in pharmaceutical manufacturing. This issue often manifests…